These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 35120484)

  • 1. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
    Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
    BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.
    Chen L; Yuan L; Wang Y; Wang G; Zhu Y; Cao R; Qian G; Xie C; Liu X; Xiao Y; Wang X
    Int J Biol Sci; 2017; 13(11):1361-1372. PubMed ID: 29209141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of TYROBP and FCER1G as Key Genes with Prognostic Value in Clear Cell Renal Cell Carcinoma by Bioinformatics Analysis.
    Wang L; Lin Y; Yuan Y; Liu F; Sun K
    Biochem Genet; 2021 Oct; 59(5):1278-1294. PubMed ID: 33786672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
    Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
    Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining UBR5 and CD163
    Wang C; Hong T; Wang Y; Peng G; Yu Y; Zhang J; Zhuo D; Zheng J; Ma X; Cui X
    Cancer Immunol Immunother; 2021 Oct; 70(10):2925-2935. PubMed ID: 33710368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients.
    Wang C; Hong T; Wang Y; Gan S; Wang Q; Li J; Zuo L; Cui X
    Oncoimmunology; 2020; 9(1):1736793. PubMed ID: 32313718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.
    Cui Y; Zhou Z; Chai Y; Zhang Y
    J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment.
    Xu W; Liu WR; Xu Y; Tian X; Anwaier A; Su JQ; Zhu WK; Shi GH; Wei GM; Huang YP; Qu YY; Zhang HL; Ye DW
    Int J Biol Sci; 2021; 17(9):2205-2222. PubMed ID: 34239350
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
    Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
    J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive bioinformatics analysis of KIF20A as a prognosis biomarker for clear cell renal cell carcinoma.
    Xie C; Yiu W; Mo Y
    Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):116-124. PubMed ID: 38650144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
    Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
    Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy.
    Xiang Z; Shen E; Li M; Hu D; Zhang Z; Yu S
    Bioengineered; 2021 Dec; 12(1):1773-1790. PubMed ID: 34002666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
    Qiu X; Gu Y; Ni Y; Li Q
    Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
    Tang F; Lu Z; He C; Zhang H; Wu W; He Z
    BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.